As NY celebrates Aaron Judge’s 61st home run, the bigger NY/BOS matchup is tonight with Memorial Sloan Kettering Cancer Center and Dana-Farber going head to head discussing all the hot topics in MM and CML! Register now! cvent.me/3rnx9Y #mmsm Clifton Mo Shonali Midha, M.D. Saad Z. Usmani MD MBA FACP (he/his/him)

Very excited to see this incredible work led by Sham Mailankody and Eric Smith published in NEJM. An incredible bench-to-bedside story leading to real progress for our patients. Looking forward to seeing what comes next. nejm.org/doi/full/10.10…

Incredible work by the team Memorial Sloan Kettering Cancer Center led by Eric Smith Dana-Farber & Sham Mailankody of first-in-human GPRC5D CAR-T in RRMM published in NEJM #mmsm :
⭐️ORR 71% (n=17)
⭐️67% MRD (8/12)
⭐️70% obj response in prior BCMA-exposed
nejm.org/doi/full/10.10…

Looking forward to an exciting Face-Off on September 29th when we, Memorial Sloan Kettering Cancer Center take on Dana-Farber in analyzing key datasets in the treatment of patients with CML and multiple myeloma #mmsm . Register today: cvent.me/3rnx9Y Malin Hultcrantz MD PhD Carlyn Tan

Join Omar Nadeem on August 31 for a concise and informative 30-minute webinar covering abstracts from the #IMS22 meeting on advances in chimeric antigen receptor T (CAR-T) cell therapy. Register Now! bit.ly/3pNDdKk #hematology #oncology

Mezi might be my new favorite nickname for a drug! Impressive responses with PI combinations presented by Paul Richardson. Dana-Farber Myeloma Society #mmsm #IMS2022

Big congrats to Noopur Raje for this well deserved recognition! #mmsm #IMS2022

Funtional high risk MM is quite possibly the greatest unmet need in MM. Very difficult to treat population with lack of effective therapies. Need more dedicated studies in this subgroup, perhaps with early use of immunotherapies. Great presentation by Ajai Chari #mmsm #IMS2022

A huge thanks to the precursor #myeloma patients who made the PANGEA Project possible. Improved prediction of precursor disease progression helps us treat patients early & is one step closer to a cure! #ims2022 #mmsm

Amazing work by Annie. 58 percent of patients classified as low or intermediate by 20-2-20 progress faster. The dynamic Pangea model can identify those. #mmsm ⁦Annie⁩

Our initial real world experience with Abecma/ide-cel CAR T-cell therapy Dana-Farber. ORR/CR rates similar to clinical trial data but shorter PFS. Pts more heavily pretreated and with organ compromise, esp renal dysfunction. Need better strategies for maintenance #mmsm #IMS2022

Two things that myeloma patients hate the most: bone marrow biopsies and 24 hour urine collections! Shaji Kumar on the current role of urine M protein in response assessment. Hope we can increasingly use PB going forward for most things! #mmsm #IMS2022

Excellent presentation by Romanos Sklavenitis-Pistofidis on immune cell changes in HR-SMM patients treated with Elo/Len/Dex Dana-Farber Harvard Medical School Center for Prevention of Progression of Cancer Ghobrial Lab Irene Ghobrial #IMS22

Largest collaborative study from 5 countries and 237 patients with AL amyloidosis with renal transplantation and a median f/u of 8.5 years, showing overall and renal graft survival benefit. BU AMYLOIDOSIS CENTER Andrea Havasi
nature.com/articles/s4140…

On 8/17 @ 1 PM ET, Sagar Lonial MD and Omar Nadeem at Dana-Farber Harvard Medical School and Winship Cancer Institute of Emory University discuss #multiple myeloma precursor conditions. #mmsm Register here: ow.ly/ISot50K8FFr

If you have a myeloma precursor condition or know someone who does, be sure to join our webinar on 8/17 @ 1 PM ET. Sagar Lonial MD and Omar Nadeem will review MGUS and SMM, including what these conditions are and why they’re important. #mmsm To register: ow.ly/ibOg50K7L8Y

WATCH: Experts discuss frontline therapy for transplant-eligible multiple myeloma/ the role of MRD negativity. Ajai Chari Krina Patel Cristina Gasparetto Rafael Fonseca MD 🇺🇸🏜🇲🇽 Omar Nadeem Icahn School of Medicine at Mount Sinai MD Anderson Cancer Center Duke Health Mayo Clinic Dana-Farber #mymsm ow.ly/mtbO50JUVQB

doi.org/10.1038/s41467… or as a PDF here nature.com/articles/s4146…
Our manuscript is out Gad Getz Laboratory Mark Bustoros

Bispecific antibodies are showing unprecedented single agent activity in relapsed/refractory MM. There are several phase I trials in this setting, let’s see at the data shared at #ASCO22 and #EHA2022 with Teclistamab , Elranatamab and REGN5458 targeting BCMA and…